STADA appoints Nigel Stephenson to lead UK business

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023.

Based in Huddersfield, UK, Stephenson will report directly to STADA’s Head of Western Europe and Germany, Stephan Eder.

He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA’s Mid-Sized European Markets.|

A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies.

He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland.

“With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership,” stated Eder.

“Building on the strong progress made under Rudolf Bär over the past year, I am confident that Nigel will lead our team in the UK to deliver strong, sustainable growth.”

Stephenson started his career as part of the IBM Global Leaders Program in the US. He then worked for more than 9 years at Procter & Gamble, spanning local and regional marketing roles for key brands such as Ariel, before subsequently taking over cross-regional and global marketing responsibilities.

He continued his personal growth at two renowned global healthcare companies, Novartis and GSK, developing from leading regional and global marketing roles in Switzerland and Poland to general management positions for Romania & Moldova and Switzerland. In his last position as General Manager Switzerland at Haleon, Nigel successfully demonstrated exceptional leadership skills and achieved significant growth for the organization.

“I am looking forward to further strengthening the STADA growth mindset in UK, working on iconic brands such as Covonia, Care, Cetraben, Hedrin, Oilatum and Zoflora, as well as our growing Generics and Specialty portfolios in the UK,” Stephenson commented.

“Based on the strong commercial performance, product launches and employee engagement achieved under Rudolf’s leadership, I am sure that our high-performance team will continue to deliver sustainable growth and to outperform the industry.”